# Combination Chemotherapy Followed By Filgrastim or Sargramostim in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

> **NCT00053131** · PHASE2 · COMPLETED · sponsor: **Roswell Park Cancer Institute**

## Conditions studied

- Leukemia

## Interventions

- **BIOLOGICAL:** filgrastim
- **BIOLOGICAL:** sargramostim
- **DRUG:** cytarabine
- **DRUG:** mitoxantrone hydrochloride

## Key facts

- **NCT ID:** NCT00053131
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-01
- **Primary completion:** 2004-02
- **Final completion:** 2004-02
- **Target enrollment:** — (—)
- **Last updated:** 2011-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00053131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00053131, "Combination Chemotherapy Followed By Filgrastim or Sargramostim in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00053131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*